Table 1.
Baseline characteristics of the patient population
| Patient population n = 64 (100%) |
|
|---|---|
| Gender | |
| Male | 33 (51.6) |
| Female | 31 (48.4) |
| Age | |
| < 60 years | 28 (43.8) |
| ≥ 60 years | 36 (56.2) |
| GNAQ | |
| Mutated | 8 (12.5) |
| Wildtype | 8 (12.5) |
| Unknown | 48 (75.0) |
| GNA11 | |
| Mutated | 10 (15.6) |
| Wildtype | 5 (7.8) |
| Unknown | 49 (76.6) |
| ECOG status | |
| 0 | 49 (76.6) |
| 1 | 11 (17.2) |
| 2 | 1 (1.6) |
| 3 | 1 (1.6) |
| Unknown | 2 (3.1) |
| Serum LDH | |
| Normal | 28 (43.8) |
| Elevated (>ULN) | 33 (51.6) |
| Unknown | 3 (4.7) |
| Previous systemic therapies | |
| 0 | 50 (78.1) |
| 1 | 12 (18.8) |
| ≥ 2 | 2 (3.1) |
| Previous ipilimumab monotherapy | 2 (3.1) |
| Previous PD-1 inhibitor monotherapy | 12 (18.8) |
| Liver-directed therapies | |
| 0 | 33 (51.6) |
| 1 | 30 (46.9) |
| ≥ 2 | 1 (1.6) |
| Metastatic sitesa | |
| Liver | 58 (90.6) |
| Lung | 23 (35.9) |
| Bone | 17 (26.6) |
| Lymph nodes | 12 (18.8) |
| CNS | 4 (6.3) |
| Treatment regimen | |
| Ipilimumab 3 mg/kg + nivolumab 1 mg/kg Q3W, followed by nivolumab 3 mg/kg Q2W | 59 (92.2%) |
| Ipilimumab 1 mg/kg + pembrolizumab 2 mg/kg Q3W, followed by pembrolizumab 2 mg/kg Q3W | 5 (7.8%) |
aMultiple metastatic sites per patient were possible (values do not sum up to 100%); abbreviations: CNS Central nervous system, Q2W Every two weeks, Q3W Every three weeks